vs

Side-by-side financial comparison of NEXGEL, INC. (NXGL) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Vivos Therapeutics, Inc. is the larger business by last-quarter revenue ($3.8M vs $2.8M, roughly 1.4× NEXGEL, INC.). NEXGEL, INC. runs the higher net margin — -34.7% vs -180.3%, a 145.6% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -8.1%). Over the past eight quarters, NEXGEL, INC.'s revenue compounded faster (48.6% CAGR vs 5.8%).

NEXGEL, INC. is a specialty consumer healthcare and medical technology firm that develops, manufactures and distributes ultra-gentle, irritation-free hydrogel products. Its offerings span over-the-counter skincare remedies, wound care solutions, and topical drug delivery platforms, serving consumer, clinical and pharmaceutical partner segments primarily across North America, with growing global distribution channels.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

NXGL vs VVOS — Head-to-Head

Bigger by revenue
VVOS
VVOS
1.4× larger
VVOS
$3.8M
$2.8M
NXGL
Growing faster (revenue YoY)
VVOS
VVOS
+11.5% gap
VVOS
3.4%
-8.1%
NXGL
Higher net margin
NXGL
NXGL
145.6% more per $
NXGL
-34.7%
-180.3%
VVOS
Faster 2-yr revenue CAGR
NXGL
NXGL
Annualised
NXGL
48.6%
5.8%
VVOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NXGL
NXGL
VVOS
VVOS
Revenue
$2.8M
$3.8M
Net Profit
$-970.0K
$-6.9M
Gross Margin
29.3%
78.1%
Operating Margin
-43.4%
-166.8%
Net Margin
-34.7%
-180.3%
Revenue YoY
-8.1%
3.4%
Net Profit YoY
-14.1%
-143.8%
EPS (diluted)
$-0.12
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NXGL
NXGL
VVOS
VVOS
Q4 25
$2.8M
$3.8M
Q3 25
$2.9M
$6.8M
Q2 25
$2.9M
$3.8M
Q1 25
$2.8M
$3.0M
Q4 24
$3.0M
$3.7M
Q3 24
$2.9M
$3.9M
Q2 24
$1.4M
$4.1M
Q1 24
$1.3M
$3.4M
Net Profit
NXGL
NXGL
VVOS
VVOS
Q4 25
$-970.0K
$-6.9M
Q3 25
$-653.0K
$-5.4M
Q2 25
$-665.0K
$-5.0M
Q1 25
$-712.0K
$-3.9M
Q4 24
$-850.0K
$-2.8M
Q3 24
$-693.0K
$-2.6M
Q2 24
$-885.0K
$-1.9M
Q1 24
$-853.0K
$-3.8M
Gross Margin
NXGL
NXGL
VVOS
VVOS
Q4 25
29.3%
78.1%
Q3 25
42.4%
58.0%
Q2 25
43.6%
55.2%
Q1 25
42.3%
50.0%
Q4 24
37.5%
56.7%
Q3 24
39.3%
60.5%
Q2 24
20.3%
65.4%
Q1 24
12.6%
56.7%
Operating Margin
NXGL
NXGL
VVOS
VVOS
Q4 25
-43.4%
-166.8%
Q3 25
-24.7%
-69.8%
Q2 25
-22.1%
-127.4%
Q1 25
-27.7%
-129.9%
Q4 24
-27.6%
-75.9%
Q3 24
-26.8%
-68.5%
Q2 24
-73.2%
-47.8%
Q1 24
-68.8%
-110.7%
Net Margin
NXGL
NXGL
VVOS
VVOS
Q4 25
-34.7%
-180.3%
Q3 25
-22.3%
-79.6%
Q2 25
-23.1%
-131.2%
Q1 25
-25.4%
-128.1%
Q4 24
-27.9%
-76.4%
Q3 24
-23.6%
-67.8%
Q2 24
-61.5%
-47.6%
Q1 24
-67.4%
-110.1%
EPS (diluted)
NXGL
NXGL
VVOS
VVOS
Q4 25
$-0.12
$-0.58
Q3 25
$-0.08
$-0.49
Q2 25
$-0.09
$-0.55
Q1 25
$-0.09
$-0.45
Q4 24
$-0.11
$0.41
Q3 24
$-0.11
$-0.40
Q2 24
$-0.14
$-0.60
Q1 24
$-0.14
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NXGL
NXGL
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$2.0M
Total DebtLower is stronger
$588.0K
$2.9M
Stockholders' EquityBook value
$4.5M
$-1.5M
Total Assets
$10.5M
$25.2M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NXGL
NXGL
VVOS
VVOS
Q4 25
$2.0M
Q3 25
$938.0K
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$1.8M
$6.3M
Q3 24
$1.1M
$6.3M
Q2 24
$6.9M
Q1 24
$2.6M
Total Debt
NXGL
NXGL
VVOS
VVOS
Q4 25
$588.0K
$2.9M
Q3 25
$614.0K
Q2 25
$638.0K
Q1 25
$662.0K
Q4 24
$685.0K
$1.2M
Q3 24
$709.0K
$1.2M
Q2 24
$732.0K
$1.2M
Q1 24
$750.0K
Stockholders' Equity
NXGL
NXGL
VVOS
VVOS
Q4 25
$4.5M
$-1.5M
Q3 25
$5.2M
$2.5M
Q2 25
$4.7M
$4.6M
Q1 25
$5.2M
$4.4M
Q4 24
$5.8M
$8.0M
Q3 24
$4.7M
$7.7M
Q2 24
$4.2M
$6.3M
Q1 24
$4.8M
$582.0K
Total Assets
NXGL
NXGL
VVOS
VVOS
Q4 25
$10.5M
$25.2M
Q3 25
$11.6M
$25.6M
Q2 25
$9.7M
$26.0M
Q1 25
$10.4M
$11.3M
Q4 24
$11.0M
$15.3M
Q3 24
$10.6M
$15.3M
Q2 24
$9.8M
$15.8M
Q1 24
$10.4M
$11.8M
Debt / Equity
NXGL
NXGL
VVOS
VVOS
Q4 25
0.13×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.13×
Q4 24
0.12×
0.15×
Q3 24
0.15×
0.16×
Q2 24
0.18×
0.19×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NXGL
NXGL
VVOS
VVOS
Operating Cash FlowLast quarter
$281.0K
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NXGL
NXGL
VVOS
VVOS
Q4 25
$281.0K
$-3.8M
Q3 25
$-785.0K
$-4.2M
Q2 25
$-407.0K
$-3.5M
Q1 25
$-400.0K
$-3.8M
Q4 24
$-859.0K
$-2.9M
Q3 24
$-1.2M
$-4.2M
Q2 24
$-700.0K
$-3.0M
Q1 24
$-1.1M
$-2.5M
Free Cash Flow
NXGL
NXGL
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-793.0K
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-1.2M
$-4.4M
Q2 24
$-909.0K
$-3.1M
Q1 24
$-1.2M
$-2.7M
FCF Margin
NXGL
NXGL
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-27.0%
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-41.8%
-113.4%
Q2 24
-63.1%
-76.7%
Q1 24
-98.3%
-78.0%
Capex Intensity
NXGL
NXGL
VVOS
VVOS
Q4 25
40.0%
Q3 25
0.3%
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
0.4%
5.0%
Q2 24
14.5%
1.5%
Q1 24
12.0%
4.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NXGL
NXGL

Segment breakdown not available.

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons